Furazolidone-based triple therapy for H pylori gastritis in children

Table 1 Endoscopic findings

Endoscopic findings	n	%
Nodular gastritis	16	42.1
Normal	13	34.2
Duodenal ulcer or erosive bulbitis	4	10.5
Erosive duodenitis and nodular gastritis	1	2.6
Erosive gastritis	1	2.6
Nodular gastritis and esophagitis	1	2.6
Duodenal ulcer and esophagitis	1	2.6
Erosive duodenitis, esophagitis and nodular gastritis	1	2.6

Table 2 Adverse effects reported by 26 of the 38 patients

Adverse effect	n	%
Vomiting	14	36.8
Abdominal pain	13	34.2
Metallic taste	6	15.8
Diarrhea	5	13.2
Nausea	5	13.2
Dizziness	2	5.3
Headache	2	5.3
Asthenia	1	2.6
Skin rash	1	2.6

Table 3 Influence of clinical and histological variables on therapeutic success

	Eradication rate (%)	Odds ratio1	95% CI	P
Demographic data
Female gender	66.7	0.33	0.03-2.18	0.27
Age ≤ 10 yr	66.7	0.56	0.1-3.11	0.47
Indication for treatment
Ulcer-like functional dyspepsia	65.5	0.00	0.0-1.23	0.08
Initial endoscopy
Normal examination	76.9	1.30	0.23-9.44	1
Nodular gastritis2	56.2	0.24	0.03-1.39	0.08
Duodenal ulcer or erosive bulbitis	100	undefined	undefined	0.16
Histology
Intense activity	70.0	0.70	0.13-5.97	1
Moderate activity	78.9	1.73	0.32-10.17	0.46
Light activity	66.7	0.67	0.10-5.28	0.68
Intense density	75.0	1.09	0.15-13.19	1
Moderate density	73.7	1.00	0.18-5.45	1
Light density	72.7	0.93	0.16-7.01	1
Adverse effects
Yes	76.9	1.67	0.27-9.37	0.69

¹ for therapeutic success;

² without duodenal ulcer or erosive duodenitis.